View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 8, 2021

Study suggests Pfizer/BioNTech vaccine effective against Covid-19 variants

New research suggests that Pfizer/BioNTech’s mRNA Covid-19 vaccine, BNT162b2, protects against two variants of SARS-CoV-2, the virus that causes Covid-19, that have emerged in the UK and South Africa.

By Allie Nawrat

New research suggests that Pfizer/BioNTech’s mRNA Covid-19 vaccine, BNT162b2, protects against two variants of SARS-CoV-2, the virus that causes Covid-19, that have emerged in the UK and South Africa.

The research, which has been published on BioRx, was carried out by Pfizer in collaboration with scientists from the University of Texas Medical Branch.

The two variants, which are believed to be responsible for escalating Covid-19 crises in the UK and elsewhere, share a mutation in the spike protein called N501Y. They are also characterised by other, different viral mutations.

The researchers carried out lab tests on the serum of 20 participants of Pfizer’s Covid-19 vaccine trial and found that BNT162b2 successfully neutralised SARS-CoV-2 viruses engineered to contain the same N501Y mutation as the circulating variants.

The study also showed that BNT162b2-elicited human sera cause preserved neutralisation of 15 other mutations of SARS-CoV-2 that are currently circulating.

The researchers behind the study warned that these findings should be viewed with caution, not only because the paper is yet to be peer-reviewed but also because the engineered virus they relied upon did not include a full set of the spike mutations found in either the UK or South African viral strains. There is particular concern about the E484K mutation found in the South African variant.

London Metropolitan University professor of molecular immunology Gary McLean said: “It’s good news, but not surprising. The limitation is that [the study] did not construct SARS-CoV-2 with the full set of spike mutations in the UK variant and therefore further conclusions cannot be made fully at this stage.”

Pfizer and the University of Texas will continue to monitor BNT162b2’s efficacy against the other mutations found in the UK and South African variants, as well as other emerging viral mutations and strains.”

Pfizer chief scientific officer of viral vaccines Philip Dormitzer, who is one of the authors of the study, told Reuters: “So we’ve now tested 16 different mutations, and none of them have really had any significant impact. That’s the good news. That doesn’t mean that the 17th won’t.”

Researchers at the UK’s Porton Down laboratory are also seeking to determine if either the UK or South African variants of SARS-CoV-2 could make the AstraZeneca/Oxford or Pfizer/BioNTech approved vaccines less effective.

UK regulators recently approved a third Covid-19 vaccine, COVID-19 Vaccine Moderna, for temporary and emergency use in adults.

Related Companies

Free Report

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy